20170533 (AMG562 fase 1)

20170533 (AMG562 fase 1)

A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With Relapsed / Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma


Study treatment


Inclusion criteria


Exclusion criteria


Participating sites

Link